Clinical evaluation of busulfan, cladribine and alemtuzumab as reduced intensity conditioning for stem cell transplantation

Annals of Transplantation

Volumn 14, Issue 2, 2009, Pages 7-12

  Halaburda, Kazimierz ^a   Marianska, Bozena ^a   Warzocha, Krzysztof ^a   Nasilowska Adamska, Barbara ^a   Szczepinski, Andrzej ^a   Tomaszewska, Agnieszka ^a   Sawecka, Jadwiga ^a   Skulimowska, Joanna ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

Alemtuzumab; Reduced intensity conditioning; Stem cell transplantation

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BUSULFAN; CLADRIBINE; COTRIMOXAZOLE; CYCLOSPORIN; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; PENICILLIN G; TUBERCULOSTATIC AGENT; CANCER ANTIBODY; MONOCLONAL ANTIBODY; MYELOABLATIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BLOOD TRANSFUSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONSCIOUSNESS LEVEL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DONOR LYMPHOCYTE INFUSION; ERYTHROCYTE TRANSFUSION; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MENINGITIS; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROLYMPHOCYTIC LEUKEMIA; PROPHYLAXIS; REDUCED INTENSITY CONDITIONING; RELAPSE; REMISSION; SEIZURE; SIBLING; THROMBOCYTE TRANSFUSION; TREATMENT DURATION; TUBERCULOSIS; VIRUS REACTIVATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BUSULFAN; CLADRIBINE; DISEASE PROGRESSION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; REMISSION INDUCTION; TRANSPLANTATION CONDITIONING;

EID: 67649794296     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Slavin S: Immunotherapy of cancer with alloreactive lymphocytes. Lancet Oncol, 2001; 2(8): 491-98
2. Massenkeil G, Nagy M, Neuburger S et al: Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. Bone Marrow Transplant, 2005; 36(8): 683-89
3. Ortiz J, Palma-Vargas J, Wright F et al: Campath induction for kidney transplantation: report of 297 cases. Transplantation, 2008; 85(11): 1550-56
4. Filipovich AH, Weisdorf D, Pavletic S et al: National Institutes of Health consensus development project on criteria for clinical trials in chronic Graft-versus-Host-Disease: I. Diagnosis and Staging Working group report. Biol Blood Marrow Transplant, 2005; 11: 945-56
5. Aoudjhane M, Labopin M, Gorin NC et al: Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia, 2005; 19(12): 2304-12
6. Flynn CM, Hirsch B, Defor T et al: Reduced intensity compared with high dose conditioning for al-lotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am J Hematol, 2007; 82(10): 867-72
7. Markova M, Barker JN, Miller JS et al: Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic he-matopoietic stem cell transplantation: a prospective randomized trial. Bone Marrow Transplant, 2007; 39(4): 193-99
8. Ho AY, Pagliuca A, Kenyon M et al: Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute my-eloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood, 2004; 104(6): 1616-23
9. Faulkner RD, Craddock C, Byrne JL et al: BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood, 2004; 103(2): 428-34
10. Juliusson G, Theorin N, Karlsson K et al: Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival. Bone Marrow Transplant, 2006; 37(5): 503-10
11. Saito B, Fukuda T, Yokoyama et al: Impact of T-cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity regimen. Biol Blood Marrow Transplant, 2008; 14(10): 1148-55
12. Kline J, Pollyea DA, Stock W et al: Pre-trans-plant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzum-ab-based conditioning. Bone Marrow Transplant, 2006; 37(3): 307-10
13. Au WY, Leung AY, Tse EW et al: High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients. Leuk Res, 2008; 32(4): 547-51
14. Walsh R, Ortiz J, Foster P et al: Fungal and myco-bacterial infections after Campath (alemtuzumab) induction for renal transplantation. Transpl Infect Dis, 2008; 10(4): 236-39
15. Mijovic A, Abdallah A, Pearce L et al: Effects on erythropoiesis of alemtuzumab-containing reduced intensity and standard conditioning regimens. Br J Haematol, 2008; 142(3): 444-52
16. Ingram W, Devereux S, Das-Gupta EP et al: Outcome of BEAM-autologous and BEAM-alem-tuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol, 2008; 141(2): 235-43
17. Malladi RK, Peniket AJ, Littlewood TJ et al. Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML. Bone Marrow Transplant, 2008 Nov 24, [Epub ahead of print]
18. Tauro S, Craddock C, Peggs K et al: Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol, 2005; 23(36): 9387-93
19. Shaw BE, Byrne JL, Das-Gupta E et al: The impact of chimerism patterns and predonor leukocyte infusion lymphopenia on survival following T cell-depleted reduced intensity conditioned transplants. Biol Blood Marrow Transplant, 2007; 13(5): 550-59
20. Lim ZY, Pearce L, Ingram W et al: Chimerism does not predict for outcome after alemtuzumab-based conditioning: lineage-specific analysis of chimerism of specific diseases may be more informative. Bone Marrow Transplant, 2007; 40(2): 181